Nektar Therapeutics
455 Mission Bay Blvd South
San Francisco
California
94158
United States
Tel: 415-482-5300
Website: http://www.nektar.com/
Email: iaffairs@nektar.com
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners, our unique research and development pipeline of new investigational medicines in cancer and immunology, our proprietary and proven science and technology approach that fuels our discovery efforts and our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
462 articles with Nektar Therapeutics
-
Nektar Therapeutics has entered into a financing and co-development collaboration with SFJ Pharmaceuticals which will advance the development of investigational CD122-preferential IL-2–pathway agonist bempegaldesleukin for head and neck cancer.
-
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
1/6/2021
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin , is scheduled to present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 11:50 a.m. Pacific Time . The presentation and Q&A session will be accessible via a Webcast through a link poste
-
Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development
1/5/2021
Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective immediately.
-
Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million
12/22/2020
Nektar Therapeutics (NASDAQ: NKTR) today announced that it agreed to sell to entities managed by Healthcare Royalty Management, LLC (HCR) its royalties on future sales of ADYNOVATE, under Nektar's agreement with Baxalta Incorporated, a Takeda company, and MOVANTIK, under Nektar's agreement with AstraZeneca AB. Under the terms of th
-
Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer
12/15/2020
Nektar Therapeutics (NASDAQ:NKTR) today announced that the first patient has been dosed in the Phase 1/2 trial of NKTR-255, Nektar's investigational IL-15 pathway agonist, in patients with relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC) at the START Center for Cancer Care in San Antonio, TX.
-
Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting
12/7/2020
Nektar Therapeutics (NASDAQ: NKTR) today announced two nonclinical data presentations for NKTR-255, its IL-15 pathway agonist, at the 62 nd American Society of Hematology (ASH) Annual Meeting. The presentations include an oral presentation of translational research studies conducted in collaboration with researchers from Dana-Farbe
-
Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/11/2020
Nektar Therapeutics (Nasdaq: NKTR) today announced four data presentations for its I-O pipeline from three separate clinical-stage investigational agents at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
-
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
11/9/2020
Nektar Therapeutics announced that it will host a webcast analyst and investor conference call with a panel of oncology experts and company management on Wednesday, November 11, 2020, at 4:15 p.m. EST during the 2020 Society for Immunotherapy of Cancer Annual Meeting.
-
Nektar Therapeutics Reports Third Quarter 2020 Financial Results
11/5/2020
Nektar Therapeutics reported financial results for the third quarter ended September 30, 2020.
-
New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress
11/4/2020
Nektar Therapeutics (NASDAQ:NKTR) announced the presentation of additional clinical data from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, currently in development for the treatment of a range of autoimmune disorders, including systemic lupus erythematosus (
-
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress
10/29/2020
Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call at ACR 2020 with company management and Dr. Klatzmann of Sorbonne University on Wednesday, November 4, 2020 at 4:15 p.m. EST . The event will follow Wednesday's virtual release by ACR of the poster presentation of data
-
Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets
10/28/2020
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2020 on Thursday, November 5, 2020 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m.
-
Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19
10/27/2020
Nektar Therapeutics (NASDAQ: NKTR) today announced that it has received FDA clearance for an Investigational New Drug (IND) application for its investigational IL-2 pathway agent, bempegaldesleukin (BEMPEG, NKTR-214), to be evaluated in a Phase 1b clinical study in adult patients who have been diagnosed with mild COVID-19 infection
-
Vaccibody AS & Nektar Therapeutics Announce 1st Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head & Neck
8/12/2020
Vaccibody AS and Nektar Therapeutics announced that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin, Nektar's CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck.
-
Nektar Therapeutics Reports Second Quarter 2020 Financial Results
8/6/2020
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.
-
Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets
7/28/2020
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2020 on Thursday, August 6, 2020 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Paci
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
6/4/2020
Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune disorders, including systemic lupus erythematosus (SLE).
-
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
5/29/2020
Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. EDT during EULAR 2020.
-
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
5/22/2020
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery o